Abstract
Drug classes such as direct oral anticoagulants (DOACs) are relatively new; therefore, it is imperative to report their adverse effects with transparent information, and the quality of these reports in the medical science needs to be assessed. This study aimed at evaluating the quality of adverse effect reporting of DOACs against warfarin in atrial fibrillation (AF) using the Consolidated Standards of Reporting Trials (CONSORT) Harms checklist. We searched MEDLINE and Drug@FDA and identified four Food and Drug Administration-approved drugs from DOACs class and their relevant clinical trials. The data extraction form was designed using the CONSORT Statement of Harms to include 18 items. Data extraction was conducted by the first three authors independently and any discrepancies were resolved with a discussion later. Descriptive analysis was employed to measure the rate and percentage of completion of all the items in our revised CONSORT Statement of Harms checklist. Data analysis was condicted using the SPSS software version 20.0 software. All included articles were multicentered. The median number of authors was 14.78 and the median impact factor was 26.48. Eligibility criteria, interventions, outcomes, sequence generation, and baseline data were the most reported items whereas estimating the outcomes and explaining any interim analyses and stopping guidelines were the least reported items. All articles from the New England Journal of Medicine had a higher percentage of completion of items on the CONSORT checklist compared to the articles from other journals. The quality of reporting adverse effects for DOACs against warfarin in AF was found to be adequate.